制药集团提供66.1M美元购买瑞典生物技术Abliva,扩大稀有疾病组合。 Pharming Group offers $66.1M to acquire Swedish biotech Abliva, expanding its rare disease portfolio.

荷兰一家制药公司N.V.制药集团表示愿意以约6 610万美元的价格购买瑞典生物技术公司Abliva AB的所有股份。 Pharming Group N.V., a Dutch pharmaceutical company, has offered to buy all shares of Swedish biotech firm Abliva AB for about $66.1 million. Abliva开发了线粒体疾病治疗方法,其主要产品KL1333在一次重大试验中。 Abliva develops treatments for mitochondrial diseases, with its main product, KL1333, in a critical trial. 制药计划用现有资金为采购提供资金,并期望交易能够推动其后期管道,支持其成为主要罕见疾病公司的目标。 Pharming plans to finance the acquisition with existing funds and expects the deal to boost its late-stage pipeline and support its goal of becoming a leading rare disease company.